Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10284268" target="_blank" >RIV/00216208:11110/14:10284268 - isvavai.cz</a>
Alternative codes found
RIV/61383082:_____/14:#0000270
Result on the web
<a href="http://dx.doi.org/10.1136/gutjnl-2013-305667" target="_blank" >http://dx.doi.org/10.1136/gutjnl-2013-305667</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1136/gutjnl-2013-305667" target="_blank" >10.1136/gutjnl-2013-305667</a>
Alternative languages
Result language
angličtina
Original language name
Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
Original language description
Background and aim Severe adverse events (AEs) compromise the outcome of direct antiviral agent-based treatment in patients with advanced liver fibrosis due to HCV infection. HEP3002 is an ongoing multinational programme to evaluate safety and efficacy of telaprevir (TVR) plus pegylated-interferon-alpha (PEG-IFN alpha) and ribavirin (RBV) in patients with advanced liver fibrosis caused by HCV genotype 1 (HCV-1). Methods 1782 patients with HCV-1 and bridging fibrosis or compensated cirrhosis were prospectively recruited from 16 countries worldwide, and treated with 12 weeks of TVR plus PEG-IFN/RBV, followed by 12 or 36 weeks of PEG-IFN and RBV (PR) alone dependent on virological response to treatment and previous response type. Results 1587 patients completed 12 weeks of triple therapy and 4 weeks of PR tail (53% cirrhosis, 22% HCV-1a). By week 12, HCV RNA was undetectable in 85% of naives, 88% of relapsers, 80% of partial responders and 72% of null responders. Overall, 931 patients (59
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FE - Other fields of internal medicine
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Gut
ISSN
0017-5749
e-ISSN
—
Volume of the periodical
63
Issue of the periodical within the volume
7
Country of publishing house
GB - UNITED KINGDOM
Number of pages
9
Pages from-to
1150-1158
UT code for WoS article
000337917900017
EID of the result in the Scopus database
—